- Home
- Publications
- Publication Search
- Publication Details
Title
Synthetic lethality as an engine for cancer drug target discovery
Authors
Keywords
-
Journal
NATURE REVIEWS DRUG DISCOVERY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-11-11
DOI
10.1038/s41573-019-0046-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Genetic Screens Reveal FEN1 and APEX2 as BRCA2 Synthetic Lethal Targets
- (2019) Kristen E. Mengwasser et al. MOLECULAR CELL
- Genome-wide interrogation of human cancers identifies EGLN1 dependency in clear cell ovarian cancers
- (2019) Colles Price et al. CANCER RESEARCH
- WRN helicase is a synthetic lethal target in microsatellite unstable cancers
- (2019) Edmond M. Chan et al. NATURE
- Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens
- (2019) Fiona M. Behan et al. NATURE
- Werner syndrome helicase is a selective vulnerability of microsatellite instability-high tumor cells
- (2019) Simone Lieb et al. eLife
- Comprehensive Characterization of Cancer Driver Genes and Mutations
- (2018) Matthew H. Bailey et al. CELL
- Transcriptome Engineering with RNA-Targeting Type VI-D CRISPR Effectors
- (2018) Silvana Konermann et al. CELL
- Mapping the Genetic Landscape of Human Cells
- (2018) Max A. Horlbeck et al. CELL
- Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer
- (2018) Katherine A. Hoadley et al. CELL
- Regulation and Function of the PD-L1 Checkpoint
- (2018) Chong Sun et al. IMMUNITY
- Cancer-Cell-Intrinsic Mechanisms Shaping the Tumor Immune Landscape
- (2018) Max D. Wellenstein et al. IMMUNITY
- History of CRISPR-Cas from Encounter with a Mysterious Repeated Sequence to Genome Editing Technology
- (2018) Yoshizumi Ishino et al. JOURNAL OF BACTERIOLOGY
- Cas13d Is a Compact RNA-Targeting Type VI CRISPR Effector Positively Modulated by a WYL-Domain-Containing Accessory Protein
- (2018) Winston X. Yan et al. MOLECULAR CELL
- Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
- (2018) Jean-Charles Soria et al. NEW ENGLAND JOURNAL OF MEDICINE
- Field-deployable viral diagnostics using CRISPR-Cas13
- (2018) Cameron Myhrvold et al. SCIENCE
- Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6
- (2018) Jonathan S. Gootenberg et al. SCIENCE
- Genetic Mechanisms of Immune Evasion in Colorectal Cancer
- (2018) Catherine S. Grasso et al. Cancer Discovery
- Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF V600E -Mutant Colorectal Cancer
- (2018) Ryan B. Corcoran et al. Cancer Discovery
- STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
- (2018) Ferdinandos Skoulidis et al. Cancer Discovery
- Complex pattern of immune evasion in MSI colorectal cancer
- (2018) Mine Ozcan et al. OncoImmunology
- Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
- (2018) Reinhard Dummer et al. LANCET ONCOLOGY
- RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers
- (2018) Robert J. Nichols et al. NATURE CELL BIOLOGY
- PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow
- (2018) Todd A. Hopkins et al. MOLECULAR CANCER RESEARCH
- Trial watch: The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors
- (2018) Jun Tang et al. NATURE REVIEWS DRUG DISCOVERY
- COSMIC: the Catalogue Of Somatic Mutations In Cancer
- (2018) John G Tate et al. NUCLEIC ACIDS RESEARCH
- Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?
- (2017) Ian Churcher JOURNAL OF MEDICINAL CHEMISTRY
- Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
- (2017) Jacob Schachter et al. LANCET
- Multiplexed Engineering and Analysis of Combinatorial Enhancer Activity in Single Cells
- (2017) Shiqi Xie et al. MOLECULAR CELL
- Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents
- (2017) Xue Gao et al. NATURE
- RNA targeting with CRISPR–Cas13
- (2017) Omar O. Abudayyeh et al. NATURE
- Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage
- (2017) Nicole M. Gaudelli et al. NATURE
- In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target
- (2017) Robert T. Manguso et al. NATURE
- Orthologous CRISPR–Cas9 enzymes for combinatorial genetic screens
- (2017) Fadi J Najm et al. NATURE BIOTECHNOLOGY
- Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions
- (2017) Kyuho Han et al. NATURE BIOTECHNOLOGY
- Computational correction of copy number effect improves specificity of CRISPR–Cas9 essentiality screens in cancer cells
- (2017) Robin M Meyers et al. NATURE GENETICS
- Genetic interaction mapping in mammalian cells using CRISPR interference
- (2017) Dan Du et al. NATURE METHODS
- Pooled CRISPR screening with single-cell transcriptome readout
- (2017) Paul Datlinger et al. NATURE METHODS
- Diversity and evolution of class 2 CRISPR–Cas systems
- (2017) Sergey Shmakov et al. NATURE REVIEWS MICROBIOLOGY
- Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
- (2017) Andreas Hochhaus et al. NEW ENGLAND JOURNAL OF MEDICINE
- RNA editing with CRISPR-Cas13
- (2017) David B. T. Cox et al. SCIENCE
- PARP inhibitors: Synthetic lethality in the clinic
- (2017) Christopher J. Lord et al. SCIENCE
- Resistance to checkpoint blockade therapy through inactivation of antigen presentation
- (2017) Moshe Sade-Feldman et al. Nature Communications
- Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
- (2017) Angel Garcia-Diaz et al. Cell Reports
- Evaluation of RNAi and CRISPR technologies by large-scale gene expression profiling in the Connectivity Map
- (2017) Ian Smith et al. PLOS BIOLOGY
- Amplification of N-Myc is associated with a T-cell-poor microenvironment in metastatic neuroblastoma restraining interferon pathway activity and chemokine expression
- (2017) Julian P. Layer et al. OncoImmunology
- STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment
- (2016) S. Koyama et al. CANCER RESEARCH
- Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
- (2016) Jianjun Gao et al. CELL
- Dissecting Immune Circuits by Linking CRISPR-Pooled Screens with Single-Cell RNA-Seq
- (2016) Diego Adhemar Jaitin et al. CELL
- Perturb-Seq: Dissecting Molecular Circuits with Scalable Single-Cell RNA Profiling of Pooled Genetic Screens
- (2016) Atray Dixit et al. CELL
- A Multiplexed Single-Cell CRISPR Screening Platform Enables Systematic Dissection of the Unfolded Protein Response
- (2016) Britt Adamson et al. CELL
- Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
- (2016) Corey J Langer et al. LANCET ONCOLOGY
- The CRISPR-associated DNA-cleaving enzyme Cpf1 also processes precursor CRISPR RNA
- (2016) Ines Fonfara et al. NATURE
- Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
- (2016) Ying-Nan P. Chen et al. NATURE
- Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage
- (2016) Alexis C. Komor et al. NATURE
- CRISPR knockout screening outperforms shRNA and CRISPRi in identifying essential genes
- (2016) Bastiaan Evers et al. NATURE BIOTECHNOLOGY
- Systematic comparison of CRISPR/Cas9 and RNAi screens for essential genes
- (2016) David W Morgens et al. NATURE BIOTECHNOLOGY
- Multiplex gene editing by CRISPR–Cpf1 using a single crRNA array
- (2016) Bernd Zetsche et al. NATURE BIOTECHNOLOGY
- Induced protein degradation: an emerging drug discovery paradigm
- (2016) Ashton C. Lai et al. NATURE REVIEWS DRUG DISCOVERY
- A comprehensive map of molecular drug targets
- (2016) Rita Santos et al. NATURE REVIEWS DRUG DISCOVERY
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
- (2016) Mansoor R. Mirza et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- Multiplexed barcoded CRISPR-Cas9 screening enabled by CombiGEM
- (2016) Alan S. L. Wong et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5
- (2016) Konstantinos J. Mavrakis et al. SCIENCE
- MTAPdeletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells
- (2016) Gregory V. Kryukov et al. SCIENCE
- Targeted nucleotide editing using hybrid prokaryotic and vertebrate adaptive immune systems
- (2016) K. Nishida et al. SCIENCE
- C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector
- (2016) Omar O. Abudayyeh et al. SCIENCE
- Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting
- (2016) A. J. Aguirre et al. Cancer Discovery
- MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis
- (2016) Katya Marjon et al. Cell Reports
- A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†
- (2015) G. R. Blumenschein et al. ANNALS OF ONCOLOGY
- Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System
- (2015) Bernd Zetsche et al. CELL
- Epidemiology of Human Papillomavirus–Positive Head and Neck Squamous Cell Carcinoma
- (2015) Maura L. Gillison et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer
- (2015) Scott Kopetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
- (2015) Richard S Finn et al. LANCET ONCOLOGY
- Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors
- (2015) T. A. Hopkins et al. MOLECULAR CANCER RESEARCH
- Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors
- (2015) S. R. Whittaker et al. MOLECULAR CANCER THERAPEUTICS
- Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair
- (2015) Raphael Ceccaldi et al. NATURE
- Mammalian polymerase θ promotes alternative NHEJ and suppresses recombination
- (2015) Pedro A. Mateos-Gomez et al. NATURE
- Mechanism of microhomology-mediated end-joining promoted by human DNA polymerase θ
- (2015) Tatiana Kent et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
- (2015) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
- (2015) David M. Hyman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoantigens in cancer immunotherapy
- (2015) T. N. Schumacher et al. SCIENCE
- Immune evasion in cancer: Mechanistic basis and therapeutic strategies
- (2015) Dass S. Vinay et al. SEMINARS IN CANCER BIOLOGY
- Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
- (2015) W. Peng et al. Cancer Discovery
- Mechanism of microhomology-mediated end-joining promoted by human DNA polymerase θ
- (2015) Tatiana Kent et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs
- (2015) Anirudh Prahallad et al. Cell Reports
- Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation
- (2014) Luke A. Gilbert et al. CELL
- CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment
- (2014) A. DeMichele et al. CLINICAL CANCER RESEARCH
- Polymerase theta-mediated end joining of replication-associated DNA breaks in C. elegans
- (2014) S. F. Roerink et al. GENOME RESEARCH
- Residual Complexes Containing SMARCA2 (BRM) Underlie the Oncogenic Drive of SMARCA4 (BRG1) Mutation
- (2014) B. G. Wilson et al. MOLECULAR AND CELLULAR BIOLOGY
- Comprehensive molecular profiling of lung adenocarcinoma
- (2014) Eric A. Collisson et al. NATURE
- Discovery and saturation analysis of cancer genes across 21 tumour types
- (2014) Michael S. Lawrence et al. NATURE
- ARID1B is a specific vulnerability in ARID1A-mutant cancers
- (2014) Katherine C Helming et al. NATURE MEDICINE
- Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
- (2014) Benjamin J. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
- (2014) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma
- (2014) Maria Giuseppina Baratta et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers
- (2014) G. R. Hoffman et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3
- (2014) Chong Sun et al. Cell Reports
- Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies
- (2014) Glenn S Cowley et al. Scientific Data
- A Synthetic Lethality-Based Strategy to Treat Cancers Harboring a Genetic Deficiency in the Chromatin Remodeling Factor BRG1
- (2013) T. Oike et al. CANCER RESEARCH
- Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression
- (2013) Lei S. Qi et al. CELL
- CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes
- (2013) Luke A. Gilbert et al. CELL
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations
- (2013) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- The Cancer Genome Atlas Pan-Cancer analysis project
- (2013) John N Weinstein et al. NATURE GENETICS
- DGIdb: mining the druggable genome
- (2013) Malachi Griffith et al. NATURE METHODS
- Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
- (2013) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- RNA-Guided Human Genome Engineering via Cas9
- (2013) P. Mali et al. SCIENCE
- Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells
- (2013) Ophir Shalem et al. SCIENCE
- Genetic Screens in Human Cells Using the CRISPR-Cas9 System
- (2013) Tim Wang et al. SCIENCE
- Multiplex Genome Engineering Using CRISPR/Cas Systems
- (2013) L. Cong et al. SCIENCE
- Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors
- (2013) Tara R. Rheault et al. ACS Medicinal Chemistry Letters
- RNA-programmed genome editing in human cells
- (2013) Martin Jinek et al. eLife
- Getting Personal with Neoantigen-Based Therapeutic Cancer Vaccines
- (2013) N. Hacohen et al. Cancer Immunology Research
- Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience
- (2012) H. Kantarjian et al. BLOOD
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
- (2012) J. Murai et al. CANCER RESEARCH
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study
- (2012) Pasi A Jänne et al. LANCET ONCOLOGY
- Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
- (2012) Anirudh Prahallad et al. NATURE
- Passenger deletions generate therapeutic vulnerabilities in cancer
- (2012) Florian L. Muller et al. NATURE
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
- (2012) Jordi Barretina et al. NATURE
- The DNA damage response and cancer therapy
- (2012) Christopher J. Lord et al. NATURE
- A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity
- (2012) M. Jinek et al. SCIENCE
- siRNA off-target effects in genome-wide screens identify signaling pathway members
- (2012) Eugen Buehler et al. Scientific Reports
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- (2011) Caicun Zhou et al. LANCET ONCOLOGY
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
- (2010) Gideon Bollag et al. NATURE
- The landscape of somatic copy-number alteration across human cancers
- (2010) Rameen Beroukhim et al. NATURE
- International network of cancer genome projects
- (2010) Thomas J. Hudson (Chairperson) et al. NATURE
- ARID1AMutations in Endometriosis-Associated Ovarian Carcinomas
- (2010) Kimberly C. Wiegand et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- (2010) Eunice L. Kwak et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma
- (2010) Siân Jones et al. SCIENCE
- Dual Roles for DNA Polymerase Theta in Alternative End-Joining Repair of Double-Strand Breaks in Drosophila
- (2010) Sze Ham Chan et al. PLoS Genetics
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
- (2009) Tetsuya Mitsudomi et al. LANCET ONCOLOGY
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Loss-of-function genetic screens as a tool to improve the diagnosis and treatment of cancer
- (2009) J Mullenders et al. ONCOGENE
- Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT
- (2008) Charles D. Blanke et al. JOURNAL OF CLINICAL ONCOLOGY
- A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair
- (2008) Alan Ashworth JOURNAL OF CLINICAL ONCOLOGY
- Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033
- (2008) Charles D. Blanke et al. JOURNAL OF CLINICAL ONCOLOGY
- Oxygen Sensing by Metazoans: The Central Role of the HIF Hydroxylase Pathway
- (2008) William G. Kaelin et al. MOLECULAR CELL
- The art and design of genetic screens: RNA interference
- (2008) Michael Boutros et al. NATURE REVIEWS GENETICS
- Low-fidelity DNA synthesis by human DNA polymerase theta
- (2008) M. E. Arana et al. NUCLEIC ACIDS RESEARCH
- Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen
- (2008) A. Bommi-Reddy et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More